REC 617
Alternative Names: REC-617Latest Information Update: 30 Mar 2022
At a glance
- Originator Jiangsu Recbio Technology
- Class Influenza virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Influenza virus infections
Most Recent Events
- 21 Mar 2022 Jiangsu Recbio Technology plans a clinical trial for Influenza virus infections (Prevention)
- 07 Jan 2022 Preclinical trials in Influenza virus infections (Prevention) in China (Parenteral)
- 07 Jan 2022 Jiangsu Recbio Technology plans to file a BLA with the NMPA for Influenza virus infections (Prevention) in China in 2025